HAVN Life Sciences Inc. (HAVLF)
HAVN Life Sciences Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Port Moody, BC, CA. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $2,565. On trailing twelve-month figures it carries a trailing P/E of -0.01, a net margin of -8117.8%. Its beta of -0.30 implies it has historically moved less than the broad market.
HAVN Life Sciences Inc. is a biotechnology firm that specializes in the research and innovation of psychotropic compounds derived from botanical and fungal organisms. The company is also dedicated to establishing standardized, quality-controlled methodologies for extracting these psychoactive molecules, with a specific focus on Psilocybe mushroom species and their key constituents such as psilocybin, psilocin, and baeocystin. Furthermore, it develops natural health products utilizing unregulated ingredients. Founded in 2020, HAVN Life Sciences' operations are headquartered in Richmond, Canada.
HAVN Life Sciences Inc. is most often compared with the following Healthcare names: